DexCom Q4 EPS $0.50 Beats $0.43 Estimate, Sales $1.03B Beat $1.02B Estimate
Portfolio Pulse from Benzinga Newsdesk
DexCom (NASDAQ:DXCM) reported Q4 earnings of $0.50 per share, surpassing the $0.43 estimate, marking a 47.06% increase from last year. Sales reached $1.03B, exceeding the $1.02B estimate, a 26.90% increase from the previous year.
February 08, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DexCom reported a significant beat on both earnings per share and sales for Q4, indicating strong financial health and growth.
The substantial beat on both earnings per share and sales compared to analyst estimates suggests that DexCom is performing better than expected, which could lead to increased investor confidence and a potential short-term rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100